Introducing AlidaBio's EpiPlex™ Duo-Mod™ Service
In an exciting advancement for RNA analysis, AlidaBio has launched its EpiPlex™ Duo-Mod™ Service. This pioneering service allows researchers to simultaneously map and quantify vital RNA modifications, particularly m6A and inosine, while also profiling RNA expression within a single comprehensive report. This innovative service addresses the growing need for precise RNA modification detection and relative quantitation, particularly for valuable clinical samples such as fresh frozen and FFPE tissue.
The Importance of RNA Modifications in Research
RNA modifications are emerging as significant biomarkers in various clinical contexts. They offer essential insights into several biological processes, including immune dysregulation associated with autoimmune diseases, the initiation of oncogenic signals, and misprocessing related to neurodegeneration. Traditional analyses focusing solely on DNA or protein patterns may overlook crucial information that RNA modifications can provide.
How the EpiPlex Duo-Mod Service Works
The EpiPlex Duo-Mod Service utilizes AlidaBio's state-of-the-art proximity barcoding and enrichment technologies. This enables researchers to obtain comprehensive profiles of m6A, inosine, and overall gene expression using the same RNA sample. This unified approach facilitates the identification of genes whose expression levels may coincide but display different modification statuses, thus uncovering intricate biological relationships.
Enhanced Reporting with EpiScout™
All outcomes from the analysis are packaged in an EpiScout™ HTML report, featuring publication-ready visualizations. Researchers will also receive essential data files, including FASTQ, BAM, BED, TSV, and VCF formats for comprehensive downstream analysis. This thorough reporting mechanism empowers scientists with clear data interpretation capabilities, enhancing their research findings.
Insights from Early-Access Users
Researchers who have participated in early access to the EpiPlex Duo-Mod Service are already witnessing improved clarity in their RNA modification data. Dr. Akira Sassa from Chiba University shared, "Collaborating with AlidaBio's service enabled us to rapidly generate and interpret epitranscriptomic data, which was crucial for our recent publication outcomes."
Wider Implications for Scientific Discovery
According to Dr. Ina Anreiter from the University of Toronto, the barriers to accessing robust, transcriptome-wide RNA modification profiling have significantly lowered, enabling advancements across various biological research domains. Likewise, Eloy Santos-Pujol from the Cancer Epigenetics Group reported that the EpiPlex service provided rapid and high-quality data integration, which advanced their understanding of therapeutic impacts on brain aging pathways.
Linking RNA Modifications to Tumor Biology
Recent comprehensive studies emphasize the potential of RNA modifications, particularly m6A, as prognostic markers in oncology. Ongoing research reveals that specific m6A patterns correlate strongly with tumors' aggressiveness and patient prognoses. This highlights the critical need for sensitive and reliable RNA modification assays in clinical settings.
Service Specifications and Availability
The EpiPlex Duo-Mod Service can analyze m6A and inosine from just 20 ng of mRNA or 250 ng of total RNA. The service is capable of processing samples from humans, mice, and rats, with the potential for additional species upon request. AlidaBio ensures consistency and quality by managing the entire workflow—from RNA extraction to sequencing and data analysis—providing researchers with a superior product experience. Moreover, options are available for customized bioinformatics analysis if needed. Standard completion time tends to be between 6 to 8 weeks, with an expedited service available in 4 weeks.
About Alida Biosciences
Founded in 2020, Alida Biosciences is at the forefront of epitranscriptomics. The company is dedicated to transforming research with powerful, easy-to-use tools for RNA modification analysis. AlidaBio's services support groundbreaking research and innovations in therapeutics and diagnostics, backed by significant industry partners and funding.
Frequently Asked Questions
What is the EpiPlex Duo-Mod Service?
The EpiPlex Duo-Mod Service by AlidaBio allows for simultaneous mapping and quantification of m6A and inosine RNA modifications alongside RNA expression profiles.
What are the benefits of using this service?
This service provides researchers with comprehensive insights into RNA modifications and gene expression, making it easier to interpret complex biological data.
How does the service accommodate limited sample amounts?
The EpiPlex Duo-Mod Service is designed to work with very small amounts of RNA, starting from as little as 20 ng of mRNA or 250 ng of total RNA.
What types of samples can be processed?
Samples from humans, mice, and rats can be analyzed, with options for additional species based on requests.
How long does it typically take to complete the service?
The standard turnaround time for the EpiPlex Duo-Mod Service is between 6 to 8 weeks, with a faster 4-week option available.
